Antimicrobial Activities of Ceragenins against Clinical Isolates of Resistant Staphylococcus aureus

Judy N. Chin, Michael J. Rybak, Chrissy M. Cheung, and Paul B. Savage

Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan 48201, Department of Chemistry and Biochemistry, Brigham Young University, Provo, Utah 84602

Received 24 October 2006/Returned for modification 29 November 2006/Accepted 22 December 2006

The rise in the rates of glycopeptide resistance among Staphylococcus aureus isolates is concerning and underscores the need for the development of novel potent compounds. Ceragenins CSA-8 and CSA-13, cationic steroid molecules that mimic endogenous antimicrobial peptides, have previously been demonstrated to possess broad-spectrum activities against multidrug-resistant bacteria. We examined the activities of CSA-8 and CSA-13 against clinical isolates of vancomycin-intermediate S. aureus (VISA), heterogeneous vancomycin-intermediate S. aureus (hVISA), and vancomycin-resistant S. aureus (VRSA) and compared them to those of vancomycin, linezolid, and vancomycin by susceptibility testing and killing curve analysis. We also examined CSA-13 for its concentration-dependent activity, inoculum effect, postantibiotic effect (PAE), and synergy in combination with various antimicrobials. Overall, the MICs and minimal bactericidal concentrations of CSA-13 were fourfold lower than those of CSA-8. Time-kill curve analysis of the VRSA, VISA, and hVISA clinical isolates demonstrated concentration-dependent bactericidal killing. An inoculum effect was observed when a higher starting bacterial density was used, with the time required to achieve 99.9% killing reaching 1 h with a 6-log$_{10}$-CFU/ml starting inoculum, whereas it was >24 h with a 8- to 9-log$_{10}$-CFU/ml starting inoculum with 10× the MIC (P < 0.001). A concentration-dependent PAE was demonstrated with CSA-13, nearly doubling from 2× to 4× the MIC (P = 0.03). With respect to the CSA-13 antimicrobial combinations, time-kill curve analysis showed no difference in the log$_{10}$ CFU/ml at 24 h for the majority of the organisms tested. However, early synergy at 4 to 8 h was detected against the VRSA Pennsylvania strain (2002) when CSA-13 was tested in combination with gentamicin, while early additivity was demonstrated against all of the other organisms.

Staphylococcus aureus is a common, virulent pathogen associated with a variety of infections, ranging from moderate to severe, in the community as well as in the nosocomial setting. The current National Nosocomial Infection Surveillance System report describes an increase in the proportion of hospital intensive care units in which Staphylococcus aureus is resistant to methicillin from 35.9% in 1992 to 64.4% in 2003 (13, 19). Infections with methicillin-resistant S. aureus (MRSA) have led to a significant increase in the use of vancomycin, with the consequential development of intermediate and resistant pathogens, such as vancomycin-resistant enterococci, vancomycin-intermediate S. aureus (VISA), heterogeneous vancomycin-intermediate S. aureus (hVISA), and vancomycin-resistant S. aureus (VRSA).

The rise of multidrug resistance has prompted renewed interest in the development of novel antimicrobial agents. It is not surprising that pathogenic species have adopted survival strategies that circumvent resistance is critical to the long-term control of bacterial infection. One frequently studied target is the bacterial membrane. This is an appealing target, given that most structural elements are conserved and resistance to membrane-targeting antibiotics would require major changes in the bacterial membrane structure, which may influence the permeability barrier (20). Many agents that target the bacterial membrane are cationic, facially amphiphilic molecules, including endogenous antimicrobial peptides. Unlike typical amphiphilic compounds, facially amphiphilic molecules display separate hydrophilic and hydrophobic faces. Examples of facially amphiphilic antimicrobial peptides include the magainins and the human antimicrobial peptide LL37. Most antimicrobial peptides display broad-spectrum antibacterial activities and target the bacterial membrane. However, many antimicrobial peptides are difficult to synthesize and purify due to their complexity and size (23). In addition, antimicrobial peptides can be substrates for proteases, which limit their in vivo half-lives.

Recently, facially amphiphilic compounds designed to mimic the activities of antimicrobial peptides have been generated from a steroid scaffold. Li and colleagues prepared multiple series of cholic acid derivatives with amine groups appended on one face of the steroid (for example, see Fig. 1), and this non-peptide-based approach has yielded a class of compounds termed ceragenins with antibacterial activities comparable to those of antimicrobial peptides (10, 15, 17). Given that the amphiphilic properties of ceragenins and antimicrobial peptides are similar, it has been postulated that these agents share a mechanism of action that includes the depolarization of bacterial membranes (9). As a consequence of the bacterial...
membrane activities of ceragenins, they effectively permeabilize the outer membranes of gram-negative bacteria, thus making these organisms susceptible to hydrophobic antibiotics (12, 16).


FIG. 1. (A) Chemical structure of CSA-8 (molecular weight, 675.25); (B) chemical structure of CSA-13 (molecular weight, 822.94) (12).

To better understand the antibacterial activities of ceragenins, we compared the activities of two representative compounds (CSA-8 and CSA-13) to those of daptomycin, linezolid, and vancomycin against clinical isolates of VISA, hVISA, as well as VRSA. We also examined CSA-13 for concentration-dependent activity, inoculum effect, postantibiotic effect (PAE), and synergy in combination with various antimicrobials.

### MATERIALS AND METHODS

**Bacterial strains.** Fifty clinical isolates of hVISA and VISA as well as 4 clinical isolates of VRSA from NARSA and the clinical collections of Keiichi Hiramatsu, Tokyo, Japan, and the Anti-Infective Research Laboratory, Detroit, MI, were used for susceptibility testing (Mu50; Mi14379; Nj-992; Mu3; hVISA SA-118; VISA SA-179; ATCC 25923 control; SA-494 control; and four clinical strains of VRSA, including the Pennsylvania, Michigan, and New York strains) (4–6, 18). All hVISA strains were identified by subpopulation analysis. Four clinical isolates were selected for time-kil analysis as well as for evaluation of the postantibiotic effects. They include the prototypal strain VISA Mu50, hVISA Mu3, and VRSA strains from Pennsylvania and Michigan (VRSA-PA [2002]) and VRSA-MI [2002], respectively.

**Antimicrobial agents.** CSA-8 and CSA-13 were synthesized and provided by one of the authors (Paul B. Savage). Linezolid (analytical grade) was provided by Pfizer, Inc. Vancomycin, doxycycline, and gentamicin (analytical grade) were obtained from Sigma-Aldrich. Tigecycline and daptomycin (analytical-grade powders) were provided by Wyeth and Cubist Pharmaceuticals, respectively.

**Medium.** Mueller-Hinton broth (Difco Laboratories, Detroit, MI) supplemented with magnesium (12.5 mg/liter) and calcium (25 mg/liter) was used for all microdilution susceptibility testing and time-kil analyses. In addition, Mueller-Hinton broth adjusted with 50 mg/liter calcium and 12.5 mg/liter magnesium was used for the daptomycin studies (11, 14). Trypticase soy agar (Difco Laboratories) was used for growth and quantification of organisms.

**Susceptibility testing.** MICs as well as MBCs were determined by standardized broth microdilution techniques with a starting inoculum of $5 \times 10^8$ CFU/ml, according to Clinical and Laboratory Standards Institute guidelines, and incubation for 24 h at 35°C. MICs were determined in duplicate, with broth microdilution testing being performed up to an MIC of 32 μg/ml for both CSA-8 and CSA-13.

**Time-kil analysis.** Time-kil experiments were performed with CSA-13 and four clinical isolates (isolates Mu3, Mu50, VRSA-PA, and VRSA-MI) in triplicate. A starting inoculum of $5 \times 10^8$ CFU/ml as well as a high starting inoculum of $1 \times 10^5$ to $1 \times 10^7$ CFU/ml was used to determine whether there was an inoculum effect on CSA-13. CSA-13 was tested at 0.5×, 1×, 4×, and 10× the MIC for both starting inocula of 10^8 and 10^9 CFU/ml. Tests with CSA-13 alone and in combination with gentamicin, doxycycline, linezolid, vancomycin, tigecycline, and daptomycin at 0.5× the MIC with a starting inoculum of $1 \times 10^6$ CFU/ml were also performed for combination time-kil testing. Aliquots (0.1 ml) were removed from the cultures at 0, 1, 4, 8, and 24 h and were serially diluted in cold 0.9% sodium chloride. Synergy, additivity, antagonism, and indifference were defined as follows: $>2$-log killing, $<2$-log but $>1$-log killing, $>1$-log growth, and $\pm 1$-log killing, respectively. Bacterial counts were determined by spiral plating if appropriate dilutions by use of an automatic spiral plater (WASP, DW Scientific, West Yorkshire, England) and by counting the colonies with a colony counter (Synoptics Limited, Frederick, MD). The lower limit of detection for the colony counts was $2 \log_{10}$ CFU/ml.

**PAE.** The PAE was determined by the equation $T - C$, where $T$ refers to the time required for the CFU count to increase $1 \log_{10}$ above the count observed immediately after drug removal, and $C$ refers to the time required for the CFU count in an untreated control culture to increase $1 \log_{10}$ above the count observed immediately after completion of the same procedure with the test culture used for drug removal. PAE was determined by using the method of rapid drug removal by repeated washing, dilution, filtration, or drug inactivation. For a concentration-dependent effect with PAE, the four selected clinical strains were exposed to CSA-13 for 0.5 h at 1×, 2×, and 4× the MIC.

**Statistical analysis.** Statistical analysis was performed with SPSS statistical software (release 14.0; SPSS, Inc., Chicago, IL). Colony counts at 8 and 24 h and the time to 99.9% killing ($T_{99.9}$) were compared between groups by using one-way analysis of variance, followed by Tukey's post hoc test for multiple comparisons. A $P$ value of $\leq 0.05$ indicated statistical significance.
RESULTS

Susceptibility. Susceptibility testing of the clinical isolates demonstrated that the MIC$_{50}$, MIC$_{90}$, and MBC of CSA-8 were 4, 8, and 8 mg/liter, respectively (n = 50) (Table 1). Overall, the MICs and MBCs of CSA-13 were fourfold lower than those of CSA-8. The MIC$_{50}$ and MIC$_{90}$ of CSA-13 were lower than those of vancomycin, and the MIC$_{90}$ of CSA-13 was lower than that of linezolid. In addition, the susceptibility data for CSA-8 and CSA-13 were also the same for the four VRSA strains tested (Table 1). Both the MICs and MBCs of CSA-13 were lower than those of linezolid, vancomycin, and CSA-8 (by fourfold) for most of the VRSA isolates.

Concentration-dependent bactericidal killing. Time-kill curve analysis of the VRSA, VISA, and hVISA clinical isolates demonstrated concentration-dependent bactericidal killing, with 10$\times$ the MIC of CSA-13 achieving the earliest killing (1 h) for all isolates tested. Bactericidal killing (detection limit, 99.9%) was distinct and statistically different at 24 h and 1 h when CSA-13 was tested at 0.5$\times$ and 10$\times$ the MIC ($P < 0.002$) against all four strains. Bactericidal killing was observed at 24, 8, and 1 h at 0.5$\times$, 1$\times$, 4$\times$, and 10$\times$ the MIC, respectively, for Mu3 (Fig. 2). At 1$\times$ and 4$\times$ the MIC, the times to bactericidal kill (T$_{99.9\%}$) were 8 h and 4 h, respectively, for all of the isolates except VRSA-MI. With VRSA-MI, bactericidal killing was similar with 1$\times$ and 4$\times$ the MIC at 4 h (Fig. 3). However, time-kill curve analysis of all four strains demonstrated bactericidal killing from 1.72 to 3.92 log$_{10}$ CFU/ml by 8 h, with a mean killing of −3.4 ± 0.65 log$_{10}$ CFU/ml (median, −3.69 log$_{10}$ CFU/ml) at 8 h and a mean killing of −3.75 ± 0.07 log$_{10}$ CFU/ml (median, −3.74 log$_{10}$ CFU/ml) at 24 h when the organism was tested at all four concentrations.

An inoculum effect was also observed for CSA-13 at a starting bacterial density of 8 to 9 log$_{10}$ CFU/ml compared to that achieved with a starting bacterial density of 6 log$_{10}$ CFU/ml. At 1$\times$, 4$\times$, and 10$\times$ the MICs for Mu3, Mu50, and VRSA-PA, the T$_{99.9\%}$ were 8, 4, and 1 h, respectively, at an inoculum of 6 log$_{10}$ CFU/ml, whereas the T$_{99.9\%}$ were ≥24 h at an inoculum of 8 to 9 log$_{10}$ CFU/ml. For VRSA-MI at 1$\times$, 4$\times$, and 10$\times$ the MIC, the T$_{99.9\%}$ were 4, 4, and 1 h, respectively, at 6 log$_{10}$ CFU/ml, whereas they were ≥24 h at 8 to 9 log$_{10}$ CFU/ml (P ≤ 0.001) (Fig. 3). In fact, the time to bactericidal killing extended beyond 24 h at 1$\times$, 4$\times$, and 10$\times$ the MIC with the higher inoculum. In addition, there was a difference in bacterial killing between the higher and the lower inoculum densities for all the isolates tested with CSA-13 at 0.5$\times$, 1$\times$, and 10$\times$ the MIC at both 8 h and 24 h (P ≤ 0.05). A difference in bacterial killing between the two inocula was also detected for Mu3 at 24 h when it was tested with CSA-13 at 4$\times$ the MIC (P ≤ 0.001). A

![Mu3](image1)

FIG. 2. Time-kill curve of CSA-13 activity against Mu3 at 0.5$\times$, 1$\times$, 4$\times$, and 10$\times$ the MIC over a 24-h period. GC, growth control of the organism. The limit of detection is 2 log$_{10}$ CFU/ml.

![VRSA-MI](image2)

FIG. 3. Time-kill curve of CSA-13 activity with starting densities of both 6 log$_{10}$ CFU/ml (closed circles) and 8 to 9 log$_{10}$ CFU/ml (open circles) at 1$\times$, 4$\times$, and 10$\times$ the MIC. The limit of detection is 2 log$_{10}$ CFU/ml.

### Table 1. Activities of CSA-13, CSA-8, and comparator antimicrobial agents of 4 clinical strains of VRSA and 50 clinical isolates of hGISA and GISA

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CSA-13</td>
<td>1–2/1–2</td>
<td>1/1</td>
<td>1/1</td>
<td>1/1</td>
<td>1/1</td>
<td>1/1</td>
</tr>
<tr>
<td>Daptomycin</td>
<td>0.125–1/0.125–1–0.5/0.5</td>
<td>0.125/0.125</td>
<td>0.5/1</td>
<td>0.125/0.125</td>
<td>0.5/1</td>
<td>0.125/0.125</td>
</tr>
<tr>
<td>Linezolid</td>
<td>0.25–2/0.5–6–4/8</td>
<td>1/6</td>
<td>2/4</td>
<td>2/8</td>
<td>0.25/0.5</td>
<td></td>
</tr>
<tr>
<td>Vancomycin</td>
<td>1–8/1–16</td>
<td>8/8</td>
<td>8/8</td>
<td>8/8</td>
<td>8/8</td>
<td>8/8</td>
</tr>
</tbody>
</table>

* hGISA/GISA, glycopeptide-intermediate S. aureus; heterogeneous glycopeptide-intermediate S. aureus.
concentration-dependent effect of CSA-13 was also demonstrated in the PAE. The PAE nearly doubled at 2.28 ± 0.5 h (average ± standard deviation) when the VRSA strains and Mu3 were exposed to CSA-13 at 4× the MIC compared to that at 2× the MIC (P = 0.03) (Fig. 4). PAE also increased accordingly by 1.13 ± 0.51 h (average ± standard deviation) upon exposure to CSA-13 from 1× to 2× the MIC for all four strains and by 1.58 ± 0.92 h upon exposure to CSA-13 from 2× to 4× the MIC for Mu50.

**Combination testing.** Overall, the addition of other antimicrobial agents to CSA-13 did not improve the activity of CSA-13 since the agent was so potent when it was used alone. Time-kill curve analysis of the clinical isolates showed no difference in the log killing at 24 h for the majority of the organisms tested with CSA-13 in combination with gentamicin, doxycycline, linezolid, vancomycin, tigecycline, and daptomycin. Specifically, the combinations with doxycycline and tigecycline demonstrated indifference at all time points (1, 4, 8, and 24 h). However, early synergy at 4 h was detected against VRSA-PA when it was tested with CSA-13 plus gentamicin, whereas early additivity was demonstrated at 4, 4, and 8 h with CSA-13, Mu50, and Mu3, respectively (Fig. 5). In addition, early additivity at 4 to 8 h was detected against Mu3, Mu50, and VRSA-PA when they were tested with CSA-13 plus daptomycin, CSA-13 plus linezolid, and CSA-13 plus vancomycin, respectively.

**DISCUSSION**

Ceragenins are unique, low-molecular-mass compounds that have potent bactericidal activities against both gram-negative and gram-positive bacteria, particularly clinically relevant pathogens like MRSA. Susceptibility data from our study demonstrated that CSA-13 has an MIC/minimum bactericidal concentration (MBC) ratio of 1, suggesting bactericidal activity. This was confirmed by time-kill analysis, which demonstrated that CSA-13 has potent bactericidal activity even at a concentration of 0.5× the MIC. Indeed, various CSA-13 concentrations, i.e., those at, below, and above the MIC, demonstrated concentration-dependent antimicrobial activities. This phenomenon was also demonstrated with the postantibiotic effect.

In addition, varying the initial inoculum size in the time-kill studies showed an inoculum effect with CSA-13. Further increasing the inoculum to 10^9 CFU/ml substantially prolonged the time to 99.9% killing, i.e., from 1 h to 24 h at 10× the MIC, by testing with VRSA-MI. This inoculum effect is similar to that described in previous reports on beta-lactams and glycopeptides and may be a reflection of CSA-13’s mechanism of action, given that the literature has suggested that antimicrobials targeting the cell wall have been associated with an inoculum effect (3, 21). Combination time-kill studies demonstrated that CSA-13 is a potent agent when it is used by itself. Early synergy and additivity were noted with the combination of gentamicin and CSA-13 at 4 to 8 h; but they were not noted at 24 h, as CSA-13 killed the isolates to the detection limit on its own. This result is similar to those of other studies of the use of gentamicin in combination, which found early synergy with bactericidal agents, such as daptomycin, an antimicrobial agent that targets the bacterial membrane (8, 22). Tsuji and Rybak found that the addition of a single high dose of gentamicin (5 mg/kg of body weight) to daptomycin resulted in early bactericidal killing and synergy at 4 h, whereas bactericidal killing was achieved at 32 h when daptomycin was used alone at 6 mg/kg in a 96-h simulated in vitro pharmacodynamic/pharmacokinetic model with simulated endocardial vegetations (22). Dawis et al. also found synergy in vitro in 20% of MRSA isolates and 60% of *Pseudomonas aeruginosa* isolates tested with gatifloxacin alone or in combination with gentamicin (7). Another gentamicin combination study by Anadiotis et al. found synergy in vitro against 38.5% and 84.7% of the *S. pneumoniae* isolates tested with the beta-lactam penicillin (which targets the penicillin binding proteins in the bacterial membrane) and gentamicin at concentrations of 1 mg/liter and 2 mg/liter, respectively (1).

Our findings of CSA-13’s potent bactericidal activity against clinically relevant gram-positive pathogens are similar to those
of previous studies performed by Savage et al. (45th ICAAC, abstr. F-1231 and F-1232) and Bogdanovich et al. (45th ICAAC). Similar to Bogdanovich et al. (45th ICAAC), we found bactericidal activity by 24 h in all the isolates tested with 1/H11003 and 4/H11003 the MIC as well as demonstrated killing against the VRSA strains, Savage et al. (45th ICAAC, abstr. F-1231) reported an MIC50 and MIC90 of 0.5 mg/liter for 32 clinical isolates of MRSA. These susceptibility data were similar to the MIC50 and MIC90 of 1 mg/liter that we have reported here for the 50 clinical isolates of S. aureus (VISA and hVISA strains) with raised vancomycin MICs. Both CSA-8 and CSA-13 are promising antimicrobials and may have important therapeutic implications for infections caused by hVISA and VISA strains. Given that these small compounds are experimental antimicrobial agents, future safety, efficacy, and pharmacokinetic studies in vivo should be performed to correlate these promising in vitro data.

REFERENCES


